MedTrace Logo

SARS-CoV-2 Specific Immune Response After COVID-19 Vaccination in Cancer Patients

NCT05313074 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 311

Last updated 2022-04-15

No results posted yet for this study

Summary

Our study highlights a low degree of neutralization-afforded protection mounted by CoronaVac in cancer patients when compared with healthy volunteers, especially patients who received chemotherapy. Further booster doses, beyond the conventional two-dose regimen might be needed for recipients of CoronaVac to maintain a long-term anamnestic response.

Conditions

Interventions

BIOLOGICAL

CoronaVac vaccine

An inactivated virus COVID-19 vaccine developed by the Chinese company Sinovac Biotech.

Sponsors & Collaborators

  • Mahidol University

    collaborator OTHER

  • National Cancer Institute, Thailand

    lead OTHER_GOV

Principal Investigators

  • Thanarath Imsuwansri, MD · National Cancer Institute of Thailand

Study Design

Allocation
NON_RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-03-23
Primary Completion
2022-02-25
Completion
2022-02-25

Countries

  • Thailand

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05313074 on ClinicalTrials.gov